Thymosin Alpha-1

28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN); CAS 62304-98-7; MW 3,108.28 Da; ≥95% HPLC purity; 3,000+ PubMed publications; N-terminal acetylation confers resistance to aminopeptidase degradation
Pleiotropic Immune Signaling Research: TLR2/TLR3/TLR4/TLR7/TLR9 agonist; dendritic cell maturation (MHC-II, CD80/CD86/CD40 upregulation); T-cell differentiation (CD4+/CD8+); Th1 polarization (IL-2/IL-12/IFN-γ); NK cell activation; PD-1/Tim-3 exhaustion marker regulation
Broad Clinical Investigation: Thymalfasin (Zadaxin) — pharmaceutical with this amino acid sequence — is approved in 35+ countries; clinical investigation in COVID-19 lymphocytopenia (Liu et al., 2020), sepsis immunology meta-analyses (Liu et al., 2016; Tian et al., 2025), HBV/HCC biology, and vaccine adjuvancy research

Manufacturer: RiboCore

Availability: 100 in stock

SKU: RP-THYM

$54.00

Ship to

Shipping Method

Estimated Delivery

Price

No shipping options

Technical Specifications

Characteristic	Value
CAS Number	62304-98-7
Molecular Weight	3,108.28 Da
Molecular Formula	C₁₂₉H₂₁₅N₃₃O₅₅
Purity	≥95% (HPLC)
Form	Lyophilized powder
Sequence	Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN

Thymosin Alpha-1 (Tα1) is a synthetic 28-amino acid immunomodulatory peptide corresponding to the N-terminal fragment of prothymosin alpha, originally isolated from thymic tissue in 1977. The N-terminal acetylation confers resistance to aminopeptidase degradation and enhanced stability. With over 3,000 PubMed-indexed publications, Tα1 has been extensively characterized across TLR signaling, dendritic cell biology, T-lymphocyte maturation, and cytokine network modulation. Supplied as a lyophilized powder for in vitro research, intended strictly for qualified researchers. Certificate of Analysis (CoA) provided with every lot. Not for human or veterinary consumption.

Key Research Highlights

Research Area	Key Finding
TLR Agonism	Direct binding to TLR2/3/4/7/9 on myeloid and plasmacytoid DCs; MyD88/NF-κB and IRF3/IRF7 downstream activation; IL-12 p70 and Type I IFN induction (Romani et al., 2004)
T-Cell Biology	CD4+/CD8+ maturation; PD-1/Tim-3 exhaustion marker reduction in lymphopenic models; IL-2 receptor upregulation (Liu et al., 2020)
COVID-19 Research	Prospective cohort (Liu et al., 2020): CD4+/CD8+ restoration and exhaustion marker reduction in severe COVID-19 patients
Sepsis Immunology	Meta-analysis (Liu et al., 2016, 530 patients): Tα1 modulated immune parameters vs. control; meta-analysis (Tian et al., 2025, 706 patients): extrapancreatic infection incidence reduction

Research Applications

TLR pathway pharmacology (TLR2/3/4/7/9 agonism, MyD88/TRIF signaling)
Dendritic cell maturation and antigen presentation research
T-lymphocyte differentiation and exhaustion marker biology
Th1 cytokine network and IFN pathway research
NK cell activation and innate immunity investigation
Sepsis and systemic infection immunology models
Viral infection immunology research (hepatitis B biology, COVID-19 models)
Cancer immunotherapy mechanism investigation (HCC, melanoma models)
Vaccine adjuvancy and immunogenicity research
Antioxidant enzyme activity (SOD, GSH-Px, CAT regulation)

Research Use Only. This product is supplied for in vitro laboratory investigation by qualified researchers. Not for human or veterinary consumption, diagnosis, treatment, prevention, or cure of any condition. Not approved by the FDA for human use.